Logo

Affy Stock Climbs 5 Percent as Investment Banks Continue Upgrades

Oct 03, 2005

NEW YORK, Oct. 3 (GenomeWeb News) - Shares in Affymetrix were up 5.2 percent, or $2.40, at $48.63 in mid-afternoon trading today after the company received its third upgrade from investment banks in the last week.

 

Earlier today, investment bank Leerink Swan upgraded Affy's stock to "outperform" from "market perform." On Friday, Lehman Brothers upgraded Affy's stock to "equal-weight" from "underweight."

 

The upgrades follow last week's upgrade by investment bank Robert W. Baird to "neutral" from "underperform."

 

The upgrades come in the wake of last week's disclosure that "low initial-production yields" of the company's 500K Mapping Array Set will result in a revenue shortfall in the third quarter of as much as 13 percent.

Breaking News
The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.